Author

D. P. Cahill

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Research Focus:cell-cell communication· 2 Assay:CITE-seq· 2 Research Focus:drug response / drug discovery· 2 Assay:scRNA-seq· 2

Frequent Co-Authors

B. S. Carter· 2 shared A. A. Petti· 1 shared A. C. Wang· 1 shared A. Cingoz· 1 shared A. Dahal· 1 shared A. E. Kim· 1 shared A. H. Kim· 1 shared A. J. Livingstone· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. S. Carter

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Glioblastoma-infiltrating CD8+ T cells are predominantly a clonally expanded GZMK+ effector population

A. Z. Wang, B. L. Mashimo, M. O. Schaettler, N. D. Sherpa, L. A. Leavitt, A. J. Livingstone, S. M. Khan, M. Li, M. Anzaldua-Campos, J. D. Bradley, E. C. Leuthardt, A. H. Kim, J. L. Dowling, M. R. Chicoine, P. S. Jones, , G. P. Dunn

The paper analyzes TILs in GBM using CITE-seq and scRNA-seq to show that CD8+ T cells are predominantly clonally expanded GZMK+ effector cells, lacking canonical exhaustion.

bioRxiv · Aug 25, 2023 · PreprintImmunology

Zinc Finger MYND-Type Containing 8 (ZMYND8) is epigenetically regulated in mutant Isocitrate Dehydrogenase 1 (IDH1) glioma to promote radioresistance

S. V. Carney, K. Banerjee, A. Mujeeb, B. Zhu, S. Haase, M. L. Varela, P. Kadiyala, C. Tronrud, Z. Zhu, D. Mukherji, P. Gorla, R. Tagett, F. J. Nunez, M. Luo, W. Lou, , M. G. Castro

This paper identifies ZMYND8 as a gene epigenetically regulated by mIDH1 that promotes radioresistance in glioma cells, and shows its knockdown enhances radiosensitivity.

bioRxiv · Jun 10, 2022Cancer Biology

De Novo Pyrimidine Synthesis is a Targetable Vulnerability in IDH Mutant Glioma

D. D. Shi, M. R. Savani, M. M. Levitt, A. C. Wang, J. E. Endress, C. E. Bird, J. Buehler, S. A. Stopka, M. S. Regan, Y.-F. Lin, W. Gao, J. Khanal, M. Xu, B. Huang, R. B. Jennings, , McBray

This study identifies de novo pyrimidine synthesis as a therapeutic target in IDH mutant gliomas, showing that DHODH inhibitors are effective in preclinical models.

bioRxiv · Nov 30, 2021Cancer Biology

Microenvironmental correlates of immune checkpoint inhibitor response in human melanoma brain metastases revealed by T cell receptor and single-cell RNA sequencing

C. A. Alvarez-Breckenridge, S. C. Markson, J. H. Stocking, N. Nayyar, M. Lastrapes, M. R. Strickland, A. E. Kim, M. de Sauvage, A. Dahal, J. M. Larson, J. L. Mora, A. W. Navia, B. M. Kuter, C. M. Gill, M. S. Bertalan, , Bra

bioRxiv · Aug 25, 2021Cancer Biology

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

A. Kayabolen, E. Yilmaz, G. N. Sahin, F. Seker-Polat, A. Cingoz, B. Isik, S. Acar, S. Karahuseyinoglu, H. Wakimoto, D. P. Cahill, I. Solaroglu, A. P. Cribbs, U. Oppermann, T. Bagci-Onder

This study identifies GSK-J4 and Belinostat as effective therapies for IDH1-mutant glioma by targeting KDM6A/B and HDACs, showing synergistic effects in vitro and in vivo.

bioRxiv · Nov 26, 2020 · PreprintCancer Biology